Biotech | September 23, 2021
Aurobindo subsidiary submits MAA for oncology biosimilar
CuraTeQ Biologics is on track for filing a second oncology biosimilar
CuraTeQ Biologics is on track for filing a second oncology biosimilar
Industry leaders to increase patient access to clinical research and scale remote enrollment of participants for trial sponsors to promote increased health equity
MeMed BV is a first-of-its-kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting
This procedure is incidentally the first robotic bariatric surgery in the world to be performed in just three ports
The National Health Authority (NHA) aims to deliver 10 crore Ayushman Bharat cards in this financial year and extend free hospitalization benefits to 50 lakh people in a quarter
The net proceeds from the issue will be utilised towards the purchase of machinery, modernising existing units and expansion of its R&D facilities
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
Amptron’s R &D is based out of the US and this will enable Max to obtain US and other global certifications. Max will retain the right to market, sell and distribute the products in India.
According to WHO, over 1.5 million people died of TB in 2020
Subscribe To Our Newsletter & Stay Updated
